Tango Therapeutics Falls After Updated Pancreatic Cancer Results Offer Few Surprises

Tango Therapeutics shares dropped 13% after it released updated trial data for vopimetostat combined with daraxonrasib in pancreatic cancer. The combination produced an 82% response rate in 22 patients, down from the 92% reported earlier, and much of the data had already been disclosed in June. The company plans a front-line Phase 3 study in the first half of 2027 and is also discussing a faster approval path with the FDA.

EXPANDED:

The update covered 22 patients with MTAP-deficient pancreatic tumors; 13 were third-line. Eighteen responded, and 88% stayed progression-free at nine months, with median not reached. June’s earlier look showed 92% among 12 patients and 90% progression-free at six months. Tango also noted poor tolerability at 250 mg and Grade 3 side effects in 40% of patients on the chosen 200 mg dose.

At June’s close, Tango held $1.0 billion in cash and short-term investments, versus $380 million in March. It plans a 484-patient front-line Phase 3 against chemotherapy in the first half of 2027 and is discussing a faster second-line approval path with the FDA. It also needs sufficient daraxonrasib supply from Revolution Medicines for that trial.